Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
Open Access
- 27 October 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (1), 92-111
- https://doi.org/10.1038/s41423-020-00568-6
Abstract
The liver is an important immunological organ that controls systemic tolerance. The liver harbors professional and unconventional antigen-presenting cells that are crucial for tolerance induction and maintenance. Orchestrating the immune response in homeostasis depends on a healthy and well-toned immunological liver microenvironment, which is maintained by the crosstalk of liver-resident antigen-presenting cells and intrahepatic and liver-infiltrating leukocytes. In response to pathogens or autoantigens, tolerance is disrupted by unknown mechanisms. Intrahepatic parenchymal and nonparenchymal cells exhibit unique antigen-presenting properties. The presentation of microbial and endogenous lipid-, metabolite- and peptide-derived antigens from the gut via conventional and nonconventional mechanisms can educate intrahepatic immune cells and elicit effector responses or tolerance. Perturbation of this balance results in autoimmune liver diseases, such as autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. Although the exact etiologies of these autoimmune liver diseases are unknown, it is thought that the disruption of tolerance towards self-antigens and microbial metabolites and lipids, as well as alterations in bile acid composition, may result in changes in effector cell activation and polarization and may reduce or impair protective anti-inflammatory regulatory T and B cell responses. Additionally, the canonical and noncanonical transmission of antigens and antigen:MHC complexes via trogocytosis or extracellular vesicles between different (non) immune cells in the liver may play a role in the induction of hepatic inflammation and tolerance. Here, we summarize emerging aspects of antigen presentation, autoantibody production, and the application of novel therapeutic approaches in the characterization and treatment of autoimmune liver diseases.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB-841-Project B01, SFB841_project B01, SFB-841_project B09, SFB-841_B01, KFO_project_04)
This publication has 284 references indexed in Scilit:
- IL-10–Producing Regulatory B10 Cells Inhibit Intestinal Injury in a Mouse ModelThe American Journal of Pathology, 2011
- Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseasesNature Reviews Immunology, 2010
- Sterile inflammation: sensing and reacting to damageNature Reviews Immunology, 2010
- Antimicrobial activity of mucosal-associated invariant T cellsNature Immunology, 2010
- Candidate biomarkers in exosome‐like vesicles purified from rat and mouse urine samplesProteomics – Clinical Applications, 2010
- Identification of CD4 T-Cell Epitopes in Soluble Liver Antigen/Liver Pancreas Autoantigen in Autoimmune HepatitisGastroenterology, 2008
- A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory ResponsesImmunity, 2008
- Liver Autoimmunity Triggered by Microbial Activation of Natural Killer T CellsCell Host & Microbe, 2008
- T cell-induced secretion of MHC class II–peptide complexes on B cell exosomesThe EMBO Journal, 2007
- Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cellsProceedings of the National Academy of Sciences, 2007